Astellas Pharma
Astellas Pharma Inc. is a global pharmaceutical company headquartered in Tokyo, Japan. Established in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, Astellas focuses on the research, development, manufacture, and marketing of prescription drugs. The company operates in several therapeutic areas, primarily including urology, oncology, immunology, neuroscience, and infection. Astellas is known for its innovative products such as Xtandi (enzalutamide) for prostate cancer and Advagraf (tacrolimus) for organ transplant patients, among others.